Literature DB >> 12620741

Deaths from variant Creutzfeldt-Jakob disease in the UK.

N J Andrews1, C P Farrington, H J T Ward, S N Cousens, P G Smith, A M Molesworth, R S G Knight, J W Ironside, R G Will.   

Abstract

In 2002, 17 people died from variant CJD (vCJD) in the UK, compared with 20 in 2001 and 28 in 2000. We analysed data for deaths from vCJD since 1995 and estimated the underlying trend in mortality. The trend had a quadratic component (p=0.005), suggesting that the increase was not exponential, and that the previously increasing trend is slowing down. The death rate peaked in 2000. These findings are encouraging, but mortality might increase again in the future.

Entities:  

Mesh:

Year:  2003        PMID: 12620741     DOI: 10.1016/s0140-6736(03)12632-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances.

Authors:  Maria Caramelli; Giuseppe Ru; Pierluigi Acutis; Gianluigi Forloni
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Incidence of Creutzfeldt-Jakob disease in Taiwan: a prospective 10-year surveillance.

Authors:  Chien-Jung Lu; Yu Sun; Shun-Sheng Chen
Journal:  Eur J Epidemiol       Date:  2010-03-24       Impact factor: 8.082

3.  Informed consent should be obtained from patients to use products (skin substitutes) and dressings containing biological material.

Authors:  S Enoch; H Shaaban; K W Dunn
Journal:  J Med Ethics       Date:  2005-01       Impact factor: 2.903

4.  The prion protein gene in humans revisited: lessons from a worldwide resequencing study.

Authors:  Marta Soldevila; Aida M Andrés; Anna Ramírez-Soriano; Tomàs Marquès-Bonet; Francesc Calafell; Arcadi Navarro; Jaume Bertranpetit
Journal:  Genome Res       Date:  2005-12-20       Impact factor: 9.043

5.  Diphenylpyrazole-derived compounds increase survival time of mice after prion infection.

Authors:  Fabienne Leidel; Martin Eiden; Markus Geissen; Hans A Kretzschmar; Armin Giese; Thomas Hirschberger; Paul Tavan; Hermann M Schätzl; Martin H Groschup
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

6.  Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunohistochemical, quantitative, and biochemical study.

Authors:  Mark W Head; Diane Ritchie; Nadine Smith; Victoria McLoughlin; William Nailon; Sazia Samad; Stephen Masson; Matthew Bishop; Linda McCardle; James W Ironside
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 7.  Variant Creutzfeldt-Jakob disease.

Authors:  Esther A Croes; Cornelia M van Duijn
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

8.  The new variant of the Creutzfeldt-Jakob disease accounts for no relative increase of the Creutzfeldt-Jakob disease mortality rate in the United Kingdom; this fits ill with the new variant being the consequence of consumption of food infected with the agent of Bovine Spongiform Encephalopathy.

Authors:  Ivan Laprevotte; Alain Hénaut
Journal:  BMC Public Health       Date:  2003-08-06       Impact factor: 3.295

9.  No major change in vCJD agent strain after secondary transmission via blood transfusion.

Authors:  Matthew T Bishop; Diane L Ritchie; Robert G Will; James W Ironside; Mark W Head; Val Thomson; Moira Bruce; Jean C Manson
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

10.  Overview and evaluation of 15 years of Creutzfeldt-Jakob disease surveillance in Belgium, 1998-2012.

Authors:  Amber Litzroth; Patrick Cras; Bart De Vil; Sophie Quoilin
Journal:  BMC Neurol       Date:  2015-12-02       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.